Compare Kaltura Inc (KLTR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Kaltura Inc trades at $1.38 (market cap $212.05M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 23× Kaltura Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KLTR | TVTX | |
|---|---|---|
Market Cap | $212.05M | $4.88B |
Volume | 264,699 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $1.89 | $67.52 |
52-Week Low | $1.08 | $26.79 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $224.26M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLTR trades at $1.37, down 2.14% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported revenue of $180.85M in 2025, with a net loss of $12.07M, though losses have narrowed significantly from prior years. Recent news highlights include Gartner naming Kaltura a leader in AI for video platform services and a strategic partnership with Verimatrix for security.
The outlook remains speculative; while AI-driven growth and improving margins present upside potential, persistent losses, high valuation ratios, and negative cash flow pose substantial risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, but the stock's high volatility and weak profitability metrics warrant careful consideration.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
